Teva Pharma (TEVA) Intends to Issue $4B Offering of Sustainability-linked Senior Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teva Pharma (TEVA) Misses Q3 EPS by 6c
October 27, 2021 7:04 AM EDTTeva Pharma (NYSE: TEVA) reported Q3 EPS of $0.59, $0.06 worse than the analyst estimate of $0.65. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $4.03 billion.
GUIDANCE:
Teva Pharma reaffirms FY2021 EPS of $2.50-$2.70 and revenue of... More
Teva Pharma (TEVA) and MODAG Collaborate on Neurodegenerative Disease Drug Candidate
October 26, 2021 4:45 PM EDTTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433.
Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease... More
